Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection
详细信息 查看全文
- 作者：Masataka Tsuge ; Nobuhiko Hiraga ; Takuro Uchida ; Hiromi Kan…
- 关键词：Chronic hepatitis B ; Human hepatocyte chimeric mouse ; Chronic hepatitis B ; Anti ; HBs immunoglobulin ; Hepatitis B surface antigen loss
- 刊名：Journal of Gastroenterology
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：51
- 期：11
- 页码：1073-1080
- 全文大小：826 KB
- 刊物类别：Medicine
- 刊物主题：Medicine & Public Health<br>Gastroenterology<br>Oncology<br>Surgical Oncology<br>Hepatology<br>Internal Medicine<br>Colorectal Surgery<br>
- 出版者：Springer Japan
- ISSN：1435-5922
- 卷排序：51
文摘
Background and aimsInterferon and nucleotide/nucleoside analogues are the main treatments for chronic hepatitis B. These drugs effectively reduce serum hepatitis B virus (HBV) DNA titers but fail to sufficiently reduce hepatitis B surface antigen (HBsAg) levels. Following the recent identification of sodium taurocholate cotransporting polypeptide as a receptor for HBV entry, inhibition of HBV entry has become an attractive therapeutic target for chronic hepatitis B treatment. We therefore evaluated the antiviral effects of antibody to HBsAg (anti-HBs) immunoglobulin (HBIG), which can inhibit HBV entry, by in an vivo study and a clinical trial.